Gain Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics that target protein misfolding and dysfunction, with a lead candidate in clinical testing for Parkinson's disease and additional programs focused on lysosomal storage disorders, neurodegenerative diseases, and metabolic conditions. The company uses its proprietary Magellan computational platform to discover allosteric regulators that bind to non-competitive sites on disease-related proteins, offering potential advantages in specificity and tissue penetration over traditional active-site approaches. As a pre-revenue company, Gain Therapeutics operates through research and development funding and pursues strategic partnerships including licensing, co-development, and commercialization arrangements to advance its pipeline and build revenue.